The aggressive phenotype of Lung Cancer (LC) is defined by a high mortality rate, early metastasis, and proliferation rate. At each stage, the prognosis and available treatments vary dramatically. The illness is identified at an advanced stage even though numerous imaging investigations and invasive procedures are available. Hence, identifying biomarkers for LC early identification is crucial.
